Xcout IntelDBV Technologies S.A. competitors & alternatives
The 12 closest competitors and alternatives to DBV Technologies S.A. among biotech companies — ranked by similarity to what DBV Technologies S.A. actually does, not by market-cap band.
Subscribe to see DBV Technologies S.A.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About DBV Technologies S.A.
DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.
DBV Technologies S.A. at a glance
DBV Technologies S.A. is a biotech company headquartered in Châtillon, France. It is publicly listed (DBVT) with a market capitalisation of $615.9M. Xcout tracks 32 named people at DBV Technologies S.A., including Daniel Tasse (Chief Executive Officer & Director).
DBV Technologies S.A. leadership
- Daniel TasseChief Executive Officer & Director
- Virginie Simone Jeanine Verrechia BoucinhaChief Financial Officer
- Virginie BoucinhaChief Financial Officer
- Pharis MohideenChief Medical Officer
- James BriggsChief Human Resources Officer
- Kevin MalobiskyChief Operations Officer
26 more named people on record for DBV Technologies S.A., with roles, board committees and tenure — see the full roster →
Top 12 DBV Technologies S.A. competitors
Ranked by semantic similarity — how close each company is to DBV Technologies S.A. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
Biotechnology
Prota Therapeutics is a late clinical-stage biotechnology company headquartered in Melbourne, Australia, dedicated to advancing allergen oral immunotherapies for treating food allergies.
Biotechnology
Alladapt Immunotherapeutics is a U.S. biotechnology company developing oral immunotherapies for food allergies. Its lead product candidate, ADP101, was designed as a single treatment intended to address multiple food allergies, serving patients with food-allergic disease.
Biotechnology
Aimmune Therapeutics is a U.S. biotechnology company focused on treatments for food allergies. Its lead product, Palforzia, is an oral immunotherapy for reducing allergic reactions from accidental peanut exposure in children and adolescents with peanut allergy.
Biotechnology
Biothea Pharma, Inc. is a pharmaceutical company developing needle-free, convenient, and cost-effective alternatives for the treatment of severe allergic reactions and anaphylaxis. The company aims to provide improved therapeutic options for patients suffering from life-threatening allergic shocks.
Biotechnology
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Biotechnology
AviSia Therapeutics is a clinical-stage biotechnology company headquartered in Amsterdam, Netherlands, pioneering antigen-specific immunotherapies for autoimmune diseases. Established as a spin-off, the company develops targeted treatments to reprogram immune responses.
Similar biotech company
Egle Therapeutics SAS is a clinical-stage biotechnology company headquartered in Paris, France, that develops precision medicines designed to modulate regulatory T cells.
Biotechnology
Aravax is a biotechnology research company founded in 2015 and headquartered in Melbourne, Victoria, focusing on revolutionizing the treatment of food allergies using technology from Alfred Health and Monash University.
Similar biotech company
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Similar biotech company
Abeona Therapeutics Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of gene and cell therapies to combat critical, uncommon genetic illnesses. Their foremost developmental asset is EB-101, a personalized gene-corrected cell therapy that has progressed to Phase III clinical trials for the treatment of recessive dystrophic epidermolysis bullosa. The company's pipeline also encompasses several other programs: ABO-102, an adeno-associated virus (AAV)-based gene therapy designed for Sanfilippo syndrome type A; ABO-201, aimed at CLN3 disease; ABO-401, targeting cystic fibrosis; and ABO-50X, intended for genetic eye disorders. Additionally, Abeona actively advances AAV-based gene therapies through its proprietary AIM vector platform. Incorporated in 1974, the firm was initially named PlasmaTech Biopharmaceuticals, Inc. before officially adopting the name Abeona Therapeutics Inc. in June 2015. The company's corporate base is situated in New York, New York.
Similar biotech company
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of DBV Technologies S.A. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for DBV Technologies S.A.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →